Article Sidebar

PDF
Date Published: 27/04/2023
Abstract Views: 489
Views PDF: 194
DOI: https://doi.org/10.51298/vmj.v525i2.5176
Issue
Vol. 525 No. 2 (2023)
Section
Các bài báo
How to Cite
Nguyễn, H. B. ., Nguyễn, H. H. ., Mai , T. B. C. ., Lưu , N. T. T. ., Lê, M. K. ., & Nguyễn, T. B. S. . (2023). SURVEY OF SUBCLINICAL FEATURES AND FREQUENCY OF EGFR, KRAS MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 525(2). https://doi.org/10.51298/vmj.v525i2.5176

SURVEY OF SUBCLINICAL FEATURES AND FREQUENCY OF EGFR, KRAS MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Hoàng Bắc Nguyễn1,2, Hữu Huy Nguyễn1, Thị Bích Chi Mai 1, Nguyễn Trung Thông Lưu 1, Minh Khôi Lê1,2, Thị Băng Sương Nguyễn1,2,
1 University of Medicine and Pharmacy at Ho Chi Minh City hospital
2 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Introduction: Non-small cell lung cancer (NSCLC) is a cancer with increasing morbidity and mortality in Vietnam. Molecular assays of EGFR, KRAS are widely used to guide individualized treatment in NSCLC patients. Objective: To investigate subclinical features and frequency of EGFR, KRAS mutations in patients with non-small cell lung cancer in University medical center HCMC. Materials and Methods: DNA was isolated from 111 FFPE samples collected from NSCLC patients. DNA libraries were sequenced on NextSeq instrument (Illumina). Results:  According to NGS results, mutations were detected in EGFR (52/111, 46,8% of patients), KRAS (16/111, 14,4%). EGFR mutations were frequent in women, <60 years old, adenocarcinoma. EGFR mutations were frequent in women, <60 years old, adenocarcinoma. Meanwhile, KRAS mutations were frequent in men, ≥ 60 years old, adenocarcinoma. Conclusions: NGS allows for specific detection and precise identification of gene mutations in NSCLC patients.

Article Details

Keywords

Non-small cell lung cancer, Next-generation sequencing

References

1. Sung, Hyuna và các cộng sự. (2021), "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA: a cancer journal for clinicians. 71(3), tr. 209-249.
2. Hsu, W. H., Yang, J. H., Mok, T. S., & Loong, H. H. (2018). Overview of current systemic management of EGFR-mutant NSCLC. Annals of Oncology, 29, i3-i9.
3. Salgia, R., Pharaon, R., Mambetsariev, I., Nam, A., & Sattler, M. (2021). The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2(1), 100186.
4. Đặng Huỳnh Anh Thư, Vũ Trần Thiên Quân, Lê Xuân Trường, Nguyễn Hoài Nghĩa (2021), "Áp dụng sinh thiết lỏng phát hiện đột biến gen EGFR trên bệnh nhân UTPKTBN", Tạp chí Y học TP.HCM. 25(1), tr. 138-143.
5. Colombino, M., Paliogiannis, P., Cossu, A., Santeufemia, D. A., Sini, M. C., Casula, M.,... & Palmieri, G. (2019). EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC pulmonary medicine, 19(1), 1-10.
6. Li, D., Ding, L., Ran, W., Huang, Y., Li, G., Wang, C.,... & Xing, X. (2020). Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution. Thoracic cancer, 11(9), 2580-2589.
7. Lee, B., Lee, T., Lee, S. H., Choi, Y. L., & Han, J. (2016). Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget, 7(17), 23874.
8. Skoulidis, Ferdinandos và các cộng sự. (2021), Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p. G12C mutated non-small cell lung cancer, chủ biên, Wolters Kluwer Health.